Literature DB >> 29173709

New Insight Into the Mechanisms of Fast-Acting Antidepressants: What We Learn From Scopolamine.

Christoph Anacker1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29173709      PMCID： PMC6241293          DOI： 10.1016/j.biopsych.2017.11.001

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN： 0006-3223            Impact factor:   13.382


× No keyword cloud information.
  10 in total

1.  Brain-derived neurotrophic factor Val66Met polymorphism and antidepressant efficacy of ketamine in depressed patients.

Authors:  Gonzalo Laje; Níall Lally; Daniel Mathews; Nancy Brutsche; Anat Chemerinski; Nirmala Akula; Benjamin Kelmendi; Arthur Simen; Francis J McMahon; Gerard Sanacora; Carlos Zarate
Journal:  Biol Psychiatry       Date:  2012-07-06       Impact factor: 13.382

2.  mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists.

Authors:  Nanxin Li; Boyoung Lee; Rong-Jian Liu; Mounira Banasr; Jason M Dwyer; Masaaki Iwata; Xiao-Yuan Li; George Aghajanian; Ronald S Duman
Journal:  Science       Date:  2010-08-20       Impact factor: 47.728

3.  Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial.

Authors:  Maura L Furey; Wayne C Drevets
Journal:  Arch Gen Psychiatry       Date:  2006-10

4.  Activity-Dependent Brain-Derived Neurotrophic Factor Release Is Required for the Rapid Antidepressant Actions of Scopolamine.

Authors:  Sriparna Ghosal; Eunyoung Bang; Wenzhu Yue; Brendan D Hare; Ashley E Lepack; Matthew J Girgenti; Ronald S Duman
Journal:  Biol Psychiatry       Date:  2017-06-23       Impact factor: 13.382

5.  GABA interneurons mediate the rapid antidepressant-like effects of scopolamine.

Authors:  Eric S Wohleb; Min Wu; Danielle M Gerhard; Seth R Taylor; Marina R Picciotto; Meenakshi Alreja; Ronald S Duman
Journal:  J Clin Invest       Date:  2016-06-06       Impact factor: 14.808

6.  Genetic variant BDNF (Val66Met) polymorphism alters anxiety-related behavior.

Authors:  Zhe-Yu Chen; Deqiang Jing; Kevin G Bath; Alessandro Ieraci; Tanvir Khan; Chia-Jen Siao; Daniel G Herrera; Miklos Toth; Chingwen Yang; Bruce S McEwen; Barbara L Hempstead; Francis S Lee
Journal:  Science       Date:  2006-10-06       Impact factor: 47.728

7.  Rapid antidepressant actions of scopolamine: Role of medial prefrontal cortex and M1-subtype muscarinic acetylcholine receptors.

Authors:  Andrea Navarria; Eric S Wohleb; Bhavya Voleti; Kristie T Ota; Sophie Dutheil; Ashley E Lepack; Jason M Dwyer; Manabu Fuchikami; Astrid Becker; Filippo Drago; Ronald S Duman
Journal:  Neurobiol Dis       Date:  2015-06-21       Impact factor: 5.996

Review 8.  Adult hippocampal neurogenesis and cognitive flexibility - linking memory and mood.

Authors:  Christoph Anacker; René Hen
Journal:  Nat Rev Neurosci       Date:  2017-05-04       Impact factor: 34.870

9.  Scopolamine rapidly increases mammalian target of rapamycin complex 1 signaling, synaptogenesis, and antidepressant behavioral responses.

Authors:  Bhavya Voleti; Andrea Navarria; Rong-Jian Liu; Mounira Banasr; Nanxin Li; Rose Terwilliger; Gerard Sanacora; Tore Eid; George Aghajanian; Ronald S Duman
Journal:  Biol Psychiatry       Date:  2013-06-14       Impact factor: 13.382

Review 10.  A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders.

Authors:  Gerard Sanacora; Mark A Frye; William McDonald; Sanjay J Mathew; Mason S Turner; Alan F Schatzberg; Paul Summergrad; Charles B Nemeroff
Journal:  JAMA Psychiatry       Date:  2017-04-01       Impact factor: 21.596
  10 in total
  1 in total

1.  Activity-State Dependent Reversal of Ketamine-Induced Resting State EEG Effects by Clozapine and Naltrexone in the Freely Moving Rat.

Authors:  Christien Bowman; Ulrike Richter; Christopher R Jones; Claus Agerskov; Kjartan Frisch Herrik
Journal:  Front Psychiatry       Date:  2022-01-27       Impact factor: 4.157
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.